Analyst
MST Marquee
Dan Hurren
Healthcare Analyst
Request Access
About
Dan joined MST Marquee in 2021 to partner with senior healthcare analyst Andrew Goodsall. Dan and Andrew were the #1 ranked healthcare research team from 2004 to 2014 at Citi and UBS. Dan moved to Singapore in 2014 where he was head of the UBS Australian Sales Desk for six years. Before his equities career, Dan spent 15 years as an Australian Regular Army Officer serving in Australia and offshore. Dan has a Bachelor of Arts from the University of New South Wales and a Masters of International Studies from Sydney University. Dan Hurren is a representative of Health Finance Group Pty Ltd, who is an authorised representative of MST Financial.
Stock Coverage
Resmed Inc
RMD.AX
Integral Diagnostics Limited
IDX.AX
Neuren Pharmaceuticals Limited
NEU.AX
Capitol Health Ltd
CAJ.AX
Ansell Ltd
ANN.AX
EBOS Group Ltd
EBO.AX
Fisher & Paykel Healthcare Corporation Ltd
FPH.AX
Medical Developments International Limited
MVP.AX
Opthea Limited
OPT.AX
Oneview Healthcare PLC
ONE.AX
Alterity Therapeutics Limited
ATH.AX
Request Access
Unlock comprehensive
analyst research and insights.
Already have an account? Log in

All material on this website has been prepared by MST Financial Services Pty Limited (ABN 54 617 475 180, AFSL 500 557) for general informational purposes only and is not a solicitation of any offer to buy or sell any financial instrument or to participate in any trading strategy. Unless otherwise stated, the material presented on this site is not a research report as defined under ASIC guidance. For wholesale clients only. This material is only prepared for wholesale clients pursuant to section 761G(7) of the Corporations Act (Commonwealth). Please also refer to MST's Privacy Policy, Terms of Use and Financial Services Guide.

Some of the products referred to on this website are issued by Equity Trustees Limited (ABN 46 004 031 298, AFSL 240975), the Responsible Entity of the funds. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a company listed on the ASX (ASX: EQT). Before making any investment decision, you should carefully review the relevant disclosure documents, including the Product Disclosure Statement (PDS), Reference Guide (RG), and Target Market Determination (TMD), available from Equity Trustees. For MST Individually Managed Accounts (IMAs), please refer to the Information Memorandum. MST does not warrant the accuracy or completeness of the information provided and disclaims all liability for any errors or omissions, to the extent permitted by law. Past performance is not a reliable indicator of future performance.